Mental Health Assessment of Cancer Patients: Prevalence and Predictive Factors of Depression and Anxiety

Veroljub Vucic 1, Snezana Radovanovic 2, Svetlana Radevic 2, Zorica Savkovic 3, *Natasa Mihailovic 4, Olgica Mihaljevic 5, Ivana Zivanovic Macuzic 6, Milan Djordjic 7, Aleksandar Gavrilovic 8, Tatjana Boskovic Matic 8

1. Health Center Trstenik, Trstenik, Serbia
2. Department of Social Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
3. Faculty of Special Education and Rehabilitation, University of Belgrade, Belgrade, Serbia
4. Center for Informatics and Biostatistics, Institute of Public Health Kragujevac, Kragujevac, Serbia
5. Department of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
6. Department of Anatomy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
7. Department of Communication Skills, Ethics and Psychology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
8. Department of Neurology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

*Corresponding Author: Email: natalimihailovic@gmail.com

(Received 09 Dec 2020; accepted 16 Feb 2021)

Abstract

Background: Patients with oncological diseases often have mental disorders in the form of comorbidity. The aim of this study was to research the association of cancer with the presence of symptoms of depression and anxiety in primary health care patients.

Methods: This prospective observational study done in 2020 included adult users of health care at the Health Center Trstenik, Central Serbia, aged 19 and over, both sexes, with a diagnosis of oncological disease. A research instrument to assess depressive symptoms is used PHQ-9 (The Patient Health Questionnaire) questionnaire, derived from PRIME MD and (The Primary Care Evaluation of Mental Disorders), and the Beck Anxiety Scale (BAI) to register the presence of certain anxiety symptoms.

Results: The largest percentage of patients had symptoms of mild (27.2%) or moderate depression (22%), while 18% reported symptoms of major depression. The level of depression was higher in older subjects, in the presence of chronic diseases with greater limitations of activity and the presence of difficulties in performing daily activities, with a more pronounced effect of pain on activity, the presence of stress. All subjects were characterized as persons with severe anxiety (score 26-63). The level of anxiety was higher in older respondents, in the presence of long-term illness, with greater limitations of activities and difficulties in performing daily activities, with a more pronounced influence of pain on performing activities and the influence of the media.

Conclusion: Caring for the mental health of cancer patients must occupy a significant part of each country's national health policy.

Keywords: Mental health; Cancer patients; Depression; Anxiety
Introduction

Diagnosis of malignant disease and the process of modern and very complex treatment, can cause not only somatic problems among patients but very intense emotional reactions, with significant psychological consequences. The results of modern scientific research indicate that patients with oncological diseases often have mental disorders (in the form of comorbidity), with depressive and anxiety symptoms being the most common (1-8). Mental health disorders are directly related to the level of disability, disease progression, the presence of pain and accompanying side effects of certain chemotherapeutic drugs, sadness due to current and expected losses, fear of diagnostic and therapeutic procedures, and fear of death (9). Although the relationships between oncological diseases and mental disorders can vary (depending on the course, stage, and prognosis of the disease itself), the fact is that oncological diseases are more strongly associated with depression and anxiety than any other disease.

Besides, mental disorders can be developed from almost all types of oncological diseases and their existence can affect and cause the poorer adherence to prescribed therapeutic treatments, worsening the quality of life and increased mortality (10). Data from the literature shows the fact that patients with malignant diseases with mental disorders usually do not receive adequate treatment, despite the existence of effective psychosomatic interventions, especially for common problems such as depression and anxiety (11). Mental disorders among these patients are often unrecognized by healthcare professionals. These disorders are usually masked by the clinical picture of underlying disease symptoms or treatment effects such as fatigue, loss of appetite, sleep problems, nausea, vomiting, and may negatively affect the cooperation and treatment acceptance, functional and cognitive patient ability, quality of life, recovery, and survival (11).

The aim of this study was to research the association of cancer with the presence of symptoms of depression and anxiety in primary health care patients. The relationship between depression and anxiety among cancer patients has not been fully investigated in The Republic of Serbia, which contributes to the relevance of this research.

Materials and Methods

Study Design and Sample

The research was conducted in the form of a prospective observational study was done in 2020 which included users of health care at the Health Center Trstenik, Central Serbia, aged 19 and over, both sexes, with a diagnosis of oncological disease (inspection of medical documentation - health card).

Before the start of the study, patients were introduced to the purpose and procedure of the study and gave informed consent to participate in this study. The protocols of this research were approved by the Ethics Committee of the Health Center Trstenik, Central Serbia.

Inclusion criteria for participation in the study were patients with diagnosed oncological diseases who signed informed consent for participation in the study, while exclusion criteria were patients under 19 years of age, the presence of psychiatric illness, the presence of acute infectious (infectious) disease, the presence of chronic infectious diseases, pregnant women and patients who did not give a written consent to participate in the study.

Assessment Instruments

Besides the general questionnaire on demographic and socio-economic characteristics (European Health Survey Questionnaire - Second Wave) (12), as a research instrument to assess depressive symptoms is used PHQ-9 (The Patient Health Questionnaire) questionnaire, derived from PRIME MD- and (The Primary Care Evaluation of Mental Disorders).

PHQ-9 is a shorter form questionnaire related to the following mental problems: decreased interest or satisfaction in performing activities; discour-
agement, depression, hopelessness; sleep problems (problem falling asleep, sleeping continuously, or sleeping too much); feeling tired or lacking in energy; decreased or increased appetite; bad opinion of oneself, feeling of failure, disappointment in oneself or one's family (feeling of worthlessness or excessive or inadequate feeling of guilt); difficulty concentrating on activities such as reading newspapers or watching television (reduced ability to think, concentrate or in-decision - assessed subjectively or by others); slow movement or speech or vice versa, psychomotor restlessness and polykinesia (noticed by others, not just as a subjective feeling); suicidal thoughts. The scale consists of 9 questions with possible answers "no problem" (which is scored with zero points) or "a few days, sometimes" (which is scored with 1 point), or "more than 7 days" (which is scored with 2 points) points), or “almost every day” (which is scored with 3 points). Adding points for each answer gives a total score ranging from 0 to 27. Score values from 0 to 4 indicate the absence of depressive symptoms, a score from 5 to 9 indicates mild depressive symptoms (subsyndromal depression), and a score of 10 or more indicates a high probability of the existence of a depressive episode, which is further qualified as moderate (score from 10 to 14), moderately severe (score from 15 to 19) and severe depression (score 20 and more). Based on the PHQ-9 score, subjects were classified into one of the following categories: no depressive symptoms, mild depressive symptoms (subsyndromal depression), and depressive episode (moderate, moderate, and severe depression) (13).

The Beck Anxiety Scale (BAI) which can be used for both clinical and research purposes, in this study was not used to diagnose anxiety disorders but to register the presence of certain anxiety symptoms. Questions referred to the presence of certain symptoms of anxiety (e.g. fear of the worst, nervousness, inability to relax, fear or dread, shivering, feeling out of control, etc.). Each question has a range of four possible answers among which respondents choose one (0-no at all, 1-mild "didn't bother me much", 2-moderate "it was occasionally very uncomfortable" and 3-serious "it was almost unbearable"). The scale is graded that the first answer carries 0 and the fourth 3 points. The range of possible points on the scale ranges from 0 to 63. Based on the scores obtained on the scale, respondents were classified into one of four categories: 0-7 those with a minimum level of anxiety, 8-15 those with mild anxiety, 16-25 those with moderate anxiety, and 26-63 those with severe anxiety (14).

Social support score (Oslo-3 Social Support Scale) was formed on the basis of three questions from the questionnaire: “How many people are so close to you that you can count on them when you have serious personal problems?” , “How many people are really interested in you, in what you are doing, or in what is going on in your life?” , “How easy is for you to get practical help from neighbors if you have a need for it?” The number of points ranges from 1 to 5. After collecting points, the scores of social support were formed: a strong social support (12-14 points), moderate (9-11 points) and bad (3-8 points), (15).

Insight into the medical documentation (health card) collected data on the presence/absence of oncological diseases as well as the presence of comorbidities. The dependent variable in the study was the presence of symptoms of depression and anxiety in primary care cancer patients. Independent variables in the research were: demographic characteristics: gender, age, marital status, family structure, type of settlement; socioeconomic characteristics (occupation, education, material status); health self-assessment; health condition (presence of another chronic non-communicable disease); ability to perform daily activities; use of primary and hospital health care, unmet health care needs; determinants of health (smoking, alcohol use, physical activity, hygiene habits, eating habits, stress); social support.

**Statistical Analysis**

Descriptive statistics methods were used to present the data: tabulation and graphical representa-
The chi-square ($\chi^2$) test is used to compare differences in the frequency of categorical variables. The relationships between the dependent variable (presence/absence of depression and anxiety) and the set of independent variables were examined by univariate and multivariate logistic regression. The risk was assessed using the size of the OR (odds ratio), with a 95% confidence interval. All results where the probability is less than 5% ($P < 0.05$) were considered statistically significant. All statistical calculations were done using the commercial, standard software package SPSS, version 20.0 (Chicago, IL, USA).

## Results

### Sociodemographic Characteristics

The study included 250 patients aged 19 years and older, with a diagnosis of cancer: 174 females (69.6%) and 76 males (30.4%). Slightly more patients were from rural areas 52.4%, in the marital community 68.4%, with secondary education are 40.8% (Table 1). The most common cancers were breast cancer (28.3%), bronchial and lung cancer (7.2%), and prostate cancer (5.6%), (Table 2). When it comes to the stage of the disease, (65.7%) they were in the first stage of the disease, (33.1%) in the second, and (1.2%) in the third.

### Table 1: Sociodemographic characteristics of cancer patients

| Variables                        | N° (%)  |
|----------------------------------|---------|
| **Gender**                       |         |
| Male                             | 76 (30.4) |
| Female                           | 174 (69.6) |
| **Environment**                  |         |
| Rural                            | 131 (52.4) |
| Urban                            | 119 (47.6) |
| **Marital status**               |         |
| Unmarried                        | 5 (2) |
| Marriage                         | 171 (68.4) |
| Widow(er)                        | 50 (19.9) |
| Divorced                         | 24 (9.7) |
| **Education**                    |         |
| Without school                   | 8 (3.2) |
| Primary school                   | 91 (36.4) |
| Secondary school                 | 102 (42.4) |
| Higher school                    | 17 (6.8) |
| College/undergraduate studies    | 28 (11.2) |
| **Employment**                   |         |
| Employed                         | 115 (45.8) |
| Self-employed                    | 3 (1.2) |
| **Self-assessment of health as a whole** |             |
| Very good                        | 7 (2.8) |
| Good                             | 1 (0.4) |
| Average                          | 77 (30.8) |
| Bad                              | 161 (64.4) |
| Very bad                         | 4 (1.6) |
| **The presence of physical pain in the previous 4 weeks** |         |
| Without pain                     | - |
| Very weak                        | 31 (12.4) |
| Weak                             | 33 (13.2) |
| Moderate                         | 124 (49.6) |
| Strong                           | 61 (24.4) |
| Very strong                      | 1 (0.4) |
| Not at all                       | 6 (2.4) |
| **Influence of pain on activities** |         |
| Little                           | 48 (19.2) |
| Moderate                         | 118 (47.2) |
| Much                             | 63 (25.2) |
| Very much                        | 15 (6) |
| Strong                           | - |
| Moderate                         | 26 (10.4) |
| Bad                              | 224 (89.6) |
Table 2: The incidence of individual types of cancer in the study population

| Cancer identification on the chart | ICD mark | Localization                  | Percentage share in the study population |
|-----------------------------------|----------|-------------------------------|------------------------------------------|
| 1                                 | C00      | Lips                          | 0.8                                      |
| 2                                 | C10      | Oropharynx                    | 2.0                                      |
| 3                                 | C17      | Small intestine               | 1.6                                      |
| 4                                 | C18      | Colon                         | 4.4                                      |
| 5                                 | C19      | Sigma and rectum              | 3.6                                      |
| 6                                 | C20      | Rectum                        | 3.6                                      |
| 7                                 | C21      | Anus                          | 5.2                                      |
| 8                                 | C23      | Gallbladder                   | 1.2                                      |
| 9                                 | C25.9    | Pancreas                      | 1.6                                      |
| 10                                | C30      | Nasal cavity                  | 0.4                                      |
| 11                                | C32      | Larynx                        | 2.4                                      |
| 12                                | C33      | Trachea                       | 0.8                                      |
| 13                                | C34      | Bronchus and lungs            | 7.2                                      |
| 14                                | C43      | Melanoma                      | 3.2                                      |
| 15                                | C44      | Skin                          | 1.6                                      |
| 16                                | C45      | Pleural mesothelioma          | 0.8                                      |
| 17                                | C50      | Breast                        | 28.3                                     |
| 18                                | C51      | Vulva                         | 0.8                                      |
| 19                                | C52      | Vagina                        | 1.2                                      |
| 20                                | C53.1    | Exocervix                     | 5.2                                      |
| 21                                | C54.3    | Uterus                        | 1.2                                      |
| 22                                | C56      | Ovary                         | 2.4                                      |
| 23                                | C61      | Prostate                      | 5.6                                      |
| 24                                | C62      | Testicle                      | 0.4                                      |
| 25                                | C64      | Kidney                        | 3.6                                      |
| 26                                | C67      | Bladder                       | 3.2                                      |
| 27                                | C70      | Meninges                      | 0.4                                      |
| 28                                | C73      | Thyroid gland                 | 2.0                                      |
| 29                                | C77      | Lymph nodes                   | 4.0                                      |
| 30                                | C81.9    | Hodgkin                       | 1.2                                      |
| 31                                | C90      | Multiple myeloma              | 3.6                                      |

Prevalence and Factors Associated with Depression

The mean value of the depression score at the level of the entire study population was 11.6 ± 6.9 (range 0-25). The largest percentage of patients included in the study had symptoms of mild depression (27.2%) or moderate depression (22%), while 18% of the study population reported symptoms of major depression. There was a significant difference in PHQ-9 values among patients with different types of cancer (One-Way ANOVA, df (30) = 3,317, P <0.001). The highest mean PHQ-9 scores were found in patients with lymphoma (23.0), meningioma (22.0), and pancreatic cancer (20.8) (Table 3). The highest average values depression were recorded in patients in the third stage of the disease (21.5 ± 4.9), while the values were lower in those in the second (12.7 ± 6.7) and the first stage of the disease (10.9 ± 6.9).
Table 3: Display of PHQ-9 score values in patients with different cancers

| ICD mark | N° | PHQ-9 (Ȳ) | SD  | Min-Max    |
|----------|----|-----------|-----|------------|
| C00      | 2  | 8.5       | 0.71| 8.0–9.0    |
| C10      | 5  | 12.0      | 4.12| 7.0–15.0   |
| C17      | 4  | 13.0      | 5.03| 8.0–20.0   |
| C18      | 11 | 14.7      | 6.26| 3.0–22.0   |
| C19      | 9  | 9.4       | 8.25| 0.0–19.0   |
| C20      | 9  | 9.3       | 3.32| 4.0–15.0   |
| C21      | 13 | 12.2      | 9.32| 5.0–25.0   |
| C23      | 3  | 16.3      | 1.53| 15.0–18.0  |
| C25.9    | 4  | 20.8      | 6.5 | 11.0–24.0  |
| C30      | 1  | 4.0       |     |            |
| C32      | 6  | 10.8      | 6.85| 2.0–16.0   |
| C33      | 2  | 0         | 0   | 0.0        |
| C34      | 18 | 17.0      | 5.07| 9.0–25.0   |
| C43      | 8  | 3.8       | 3.28| 0.0–8.0    |
| C44      | 4  | 8.2       | 4.5 | 6.0–15.0   |
| C45      | 2  | 13.0      | 2.83| 11.0–15.0  |
| C50      | 71 | 9.5       | 5.93| 0.0–25.0   |
| C51      | 2  | 2.5       | 0.71| 2.0–3.0    |
| C52      | 3  | 5.0       | 5.57| 0.0–11.0   |
| C53.1    | 13 | 12.4      | 7.14| 5.0–23.0   |
| C54.3    | 3  | 8.7       | 2.89| 7.0–12.0   |
| C56      | 6  | 18.0      | 3.29| 13.0–21.0  |
| C61      | 14 | 12.6      | 6.55| 2.0–22.0   |
| C62      | 1  | 12.0      |     |            |
| C64      | 9  | 11.6      | 8.37| 2.0–23.0   |
| C67      | 8  | 17.6      | 4.95| 13.0–23.0  |
| C70      | 1  | 22.0      |     |            |
| C73      | 5  | 7.0       | 6.71| 0.0–15.0   |
| C77      | 1  | 23.0      |     |            |
| C81.9    | 3  | 16.0      | 8.66| 6.0–21.0   |
| C90      | 9  | 15.6      | 6.15| 8.0–22.0   |

Regression analysis showed a statistically significant impact of the following variables on the level of depression: lower level of education, higher absence from work, use of antihypertensives, less need for help with activities, less use of ambulances, less social support, and rural environment. The level of depression was higher in older subjects, in the presence of chronic diseases/conditions (comorbidities), with greater limitations of activity, and the presence of difficulties in performing daily activities, with a more pronounced effect of pain on activity, the presence of vision difficulties, poor oral hygiene and tension/stress (Table 4).

Prevalence and Factors Associated with Anxiety

The mean value of the anxiety score in the study population was 45.4 ± 9.5 (range 27-63). All subjects in the study were characterized as persons with severe anxiety (score 26-63).
Statistical analysis revealed a significant difference in the severity of anxiety among patients with different types of cancer (One-Way ANOVA, df (30) = 3,197, \( P < 0.001 \)). The highest mean Beck scores were found in patients with meningioma (63.0), pancreatic cancer (58.2), and lymphoma (56.0), (Table 5).

The highest average values of anxiety were recorded in patients in the third stage of the disease (53.0 ± 14.1), while the values were lower in those in the second (48.1 ± 8.9) and the first stage of the disease (44.01 ± 9.4).

Regression analysis showed a statistically significant impact of the following variables on the degree of anxiety: lower level of education, less need for help with activities, less use of home care, less activity, and social support. The level of anxiety is higher in older respondents, in the presence of long-term illness, with greater limitations of activities and difficulties in performing daily activities, with a more pronounced influence of pain on performing activities and the influence of the media (Table 6).

**Discussion**

Depressive and anxiety symptoms often appear in the form of comorbidity among patients with oncological diseases. Most cancer survivors adjust well to life after being diagnosed with cancer, but some experience permanent negative moods ranging from common feelings of vulnerability, sadness, and fear to a disability, depression, anxiety, trauma, panic, and existential crisis that disrupt normal functioning in daily activities and quality of life (16, 17).

**Table 4:** Association between characteristics and depression in cancer patients

| Variables                        | PHQ-9 exp | 95% CI for Exp (B) (lower-upper) | Odds ratio | p       |
|----------------------------------|----------|----------------------------------|------------|---------|
| Age                              | 1.9–25.8 | 10.6                             | 0.045      |
| Gender                           | 0.3–0.4  | 0.35                             | 0.961      |
| Education                        | 0.5–1.3  | 0.92                             | <0.001     |
| Environment                      | 0.3–9.2  | 4.72                             | 0.038      |
| Business hours                   | 0.9–7.6  | 4.27                             | 0.012      |
| Absence from the job             | 2.6–8.7  | 5.68                             | <0.001     |
| Activity restriction             | 2.9–6.2  | 4.62                             | <0.001     |
| Health in general                | 0.7–4.2  | 2.43                             | 0.006      |
| Chronic diseases                 | 0.4–1.8  | 1.14                             | 0.002      |
| Hypertension                     | 1.1–2.7  | 1.91                             | <0.001     |
| Use of antihypertensives         | 0.4–2.1  | 1.27                             | 0.002      |
| Vision difficulties              | 0.3–2.4  | 1.37                             | 0.013      |
| Teeth condition                  | 0.3–2.3  | 1.03                             | 0.043      |
| Difficulties in performing daily activities | 0.2–2.2 | 1.03                             | 0.042      |
| Influence of the pain on activities performance | 1.6–3.1 | 2.30                             | <0.001     |
| The need for additional help with activities | 0.9–4.2 | 2.56                             | 0.002      |
| Presence of tension/stress       | 0.6–3.7  | 1.57                             | 0.008      |
| Unmet health care needs          | 1.1–3.7  | 2.14                             | 0.001      |
| Using emergency help             | 5.3–10.4 | 7.89                             | <0.001     |
| Social support                   | 0.2–2.4  | 1.42                             | 0.036      |
Some studies indicate an increased level of anxiety and depression even years after diagnosis, which is most often caused by fear of recurrence and disease progression (18, 19).

A study examining anxiety and depression in adult cancer survivors and related factors found that 40% of cancer survivors reported moderate to high anxiety, and approximately 20% reported moderate to high depression. Higher anxiety was significantly associated with female gender, younger age, lower social support, lower physical health, and poorer family functioning (20). Being unemployed, receiving less social support, not being treated, a shorter time than diagnosis, poorer physical health, and poorer family functioning were significantly associated with higher levels of depression. Better social support, family functioning, and physical health were associated with lower anxiety and depression (20).
The studies examining levels of anxiety and depression depending on the type of cancer, according to the type of cancer revealed significant differences, so that patients with lung cancer, gynecological or hematological cancer reported the highest level of changes in mental health at the time of diagnosis (21, 22). Symptoms of depression and anxiety were more common in older patients than in younger ones, then in patients with lower education and rural areas, as well as in patients with a higher burden of symptoms and poorer physical functioning, while patients who were married were less likely to report anxiety symptoms and depression. It follows from all this that education can be a protective factor in the occurrence of depression and anxiety due to better access to information about one's health condition, understanding of treatment protocols. Also, marital union, religiosity, and spirituality are recognized as a source of support that helps the oncology patient to overcome life difficulties and stressful events such as cancer diagnosis. The higher incidence of symptoms of depression and anxiety in patients in rural areas can be explained by the poor availability of health services faced by the rural population (23, 24). The data also show that in patients with a poorer prognosis, psychological distress increases significantly in the last two to three months before death, and especially in the last month of life (25, 26). In our research the level of depression and anxiety is higher in older subjects, in the presence of comorbidities, with greater limitations of activity, and the presence of difficulties in performing daily activities, with a more pronounced effect of pain on activity.
High levels of patient suffering and quality of life for cancer patients, especially those under stress and depression, should be an important public health issue. In that sense, it is necessary to enable adequate screening for depression and anxiety among patients with oncological diseases in order to prevent mental health disorders in this population category. In addition, the gradual introduction of psycho-oncological interventions, such as counseling and psychotherapy, is a prerequisite for improving the quality of life of patients and a better prognosis of the disease (27, 28).

Conclusion

Identification of patients' psychosocial needs by health professionals, understanding of the process of coping with the disease, and timely detection of mental health disorders are important steps in the reduction of mental disorders in patients with malignant diseases. Caring for the mental health of cancer patients must occupy a significant part of each country's national health policy.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgments

This study received no financial support. The authors would like to thank all cancer patients who participated in the study.

Conflict of interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

1. Daré LO, Bruand P, Gérard D, et al (2019). Co-morbidities of mental disorders and chronic physical diseases in developing and emerging countries: a meta-analysis. BMC Public Health, 19: 304.
2. Chiu CJ, Hsu YC, Tseng SP (2017). Psychological prognosis after newly diagnosed chronic conditions: Socio-demographic and clinical correlations. Int Psychogeriatr, 29: 281–92.
3. Comijs HC, Nieuwesteeg J, Kok R, et al (2015). The two-year course of late-life depression; results from the Netherlands study of depression in older persons. BMC Psychiatry, 15: 20.
4. Kristina Geue, Philipp Göbel, Katja Leuteritz, et al (2019). Anxiety and Depression in Young Adult German Cancer Patients: Time Course and Associated Factors. Psychooncology, 28 (10): 2083-90.
5. Mitchell AJ, Chan M, Bhatti H, et al (2011). Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative care settings: a meta-analysis of 94 interview-based studies. The Lancet Oncol, 12 (2): 160–74.
6. Lu D, Andersson TM, Fall K, Hultman CM, Czene K, Valdimarsdottir U, Fang F (2016). Clinical Diagnosis of Mental Disorders Immediately Before and After Cancer Diagnosis: A Nationwide Matched Cohort Study in Sweden. JAMA Oncol, 2 (9): 1188–96.
7. Jianwei Zhu, Arvid Sjölander, Katja Fall, Unnur Valdimarsdottir, Fang Fang (2018). Mental disorders around cancer diagnosis and increased hospital admission rate - a nationwide cohort study of Swedish cancer patients. BMC Cancer, 18: 322.
8. Ozaki Y, Sposito AP, Bueno DR, Guariento ME (2015). Depression and chronic diseases in the elderly. Rev Soc Bras Clin Med, 13 (2): 149–53.

Available at: http://ijph.tums.ac.ir
9. Granek I, Nakash O, Ariad S, Shapira S, Ben-David M (2019). Strategies and Barriers in Addressing Mental Health and Suicidality in Patients With Cancer. *Oncol Nurs Forum*, 46 (5): 561-71.

10. Granek I, Nakash O, Ben-David M, Shapira S, Ariad S (2018). Oncologists’ Treatment Responses to Mental Health Distress in Their Cancer Patients. *Qual Health Res*, 28 (11): 1735-45.

11. Vuk Pisk S, Filipčić I, Bogović A, Milovac Ž, Todorić Laidlaw I, Caratan S (2017). Malignant diseases and mental disorders - prevalence, mortality, therapeutic challenge. *Soc Psychiatry*, 45: 187-201.

12. Eurostat (2013). European Health Interview Survey (EHIS wave 2). Methodological manual, 2013 Edition. Luxembourg: Publications Office of the European Union.

13. Beck AT, Steer RA (1990). Beck Anxiety Inventory (BAI) Manual. Oxford (UK): Pearson.

14. Kroenke K, Spitzer RL, Williams JB (2001). The PHQ-9: Validity of a Brief Depression Severity Measure. *J Gen Intern Med*, 16 (9): 606-13.

15. Boen H, Dalgard OS, Bjertness E (2012). The importance of social support in the associations between psychological distress and somatic health problems and socioeconomic factors among older adults living at home: a cross sectional study. *BMC Geriatr*, 12: 27.

16. Yi JC, Syrjala KL (2017). Anxiety and Depression in Cancer Survivors. *Med Clin North Am*, 101 (6): 1099-113.

17. Vehling S, Mehnerst A, Hartmann M, Oing C, Bokemeyer C, Oechsle K (2016). Anxiety and depression in long-term testicular germ cell tumor survivors. *Gen Hosp Psychiatry*, 38: 21-5.

18. Marroquin B, Czamanski-Cohen J, Weibh KL, Stanton AL (2016). Implicit loneliness, emotion regulation, and depressive symptoms in breast cancer survivors. *J Behav Med*, 39 (5): 832-44.

19. Cohee AA, Adams RN, Johns SA, B, et al (2017). Long-term fear of recurrence in young breast cancer survivors and partners. *Psychooncology*, 26 (1): 22-8.

20. Koch I, Bertram H, Eberle A, et al (2014). Fear of recurrence in long-term breast cancer survivors—still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the cancer survivorship—a multi-regional population-based study. *Psychooncology*, 23: 547–54.

21. Inhestern I, Beierlein V, Bultmann JC, et al (2017). Anxiety and depression in working-age cancer survivors: a register-based study. *BMC Cancer*, 17 (1): 347.

22. Linden W, Vodermaier A, Mackenzie R, Greig D (2012). Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. *J Affect Disord*, 141 (2-3): 343-51.

23. Swartzman S, Booth JN, Munro A, Sani F (2017). Posttraumatic stress disorder after cancer diagnosis in adults: A meta-analysis. *Depress Anxiety*, 34 (4): 327–39.

24. Hinz A, Herzberg PV, Lordick F, et al (2019). Age and gender differences in anxiety and depression in cancer patients compared with the general population. *Eur J Cancer Care (Engl)*, 28 (5): e13129.

25. Braamse AM, van Turenhout ST, Terhaar Sive Droste JS, et al (2016). Factors associated with anxiety and depressive symptoms in colorectal cancer survivors. *Eur J Gastroenterol Hepatol*, 28 (7): 831–5.

26. Muffly LS, Hluhocky FJ, Khan N, et al (2016). Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. *Cancer*, 122 (6): 954–61.

27. Tsaras K, Papathanasiou IV, Mitsi D, et al (2018). Assessment of Depression and Anxiety in Breast Cancer Patients: Prevalence and Associated Factors. *Asian Pac J Cancer Prev*, 19 (6): 1661-9.

28. Mols F, Schoormans D, de Hingh I, Oerlemans S, Husson O (2018). Symptoms of anxiety and depression among colorectal cancer survivors from the population-based, longitudinal PROFILES Registry: Prevalence, predictors, and impact on quality of life. *Cancer*, 124 (12): 2621-8.